Related Experiment Videos
[Triple oral therapy in type 2 diabetes]
1Département de médecine, CHU Sart Tilman, 4000 Liège I, Belgique. andre.scheen@chu.ulg.ac.be
Revue Medicale Suisse
|October 5, 2005
Summary
Triple oral therapy effectively targets the three main issues in type 2 diabetes: impaired insulin secretion, excess liver glucose production, and poor muscle glucose uptake. Clinical trials confirm its safety and efficacy, though its optimal role in diabetes management requires further definition.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Context:
- Type 2 diabetes involves pancreatic beta-cell dysfunction, hepatic insulin resistance, and impaired skeletal muscle glucose uptake.
- Current treatments often target individual pathophysiological defects.
- The combination of agents addressing these core defects offers a potential therapeutic strategy.
Purpose:
- To evaluate the efficacy and safety of a triple oral therapy for type 2 diabetes.
- To explore the potential role of simultaneously targeting insulin secretion, hepatic glucose production, and insulin-mediated glucose uptake.
Summary:
- Type 2 diabetes pathophysiology is characterized by defects in insulin secretion, increased hepatic glucose production, and reduced skeletal muscle glucose uptake.
- Each defect can be addressed by specific drug classes: insulin secretagogues (sulfonylureas, glinides), metformin, and thiazolidinediones (glitazones).
- Triple oral therapy combines these agents to simultaneously target the main metabolic abnormalities, showing promising efficacy and safety in recent trials.
Impact:
- Triple oral therapy presents a viable option for managing type 2 diabetes by addressing its multifaceted nature.
- Further research is needed to define the precise positioning of this combination therapy within the broader treatment landscape.
- This approach may offer improved glycemic control for patients with type 2 diabetes.